文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA PET/CT阴性在生化复发前列腺癌患者管理中的临床价值

Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-06-26

回顾性分析103例生化复发前列腺癌患者,68Ga-PSMA PET/CT阴性后随访至少1年,55.3%出现临床复发,中位无临床复发生存期15.4个月。ISUP分级是唯一显著复发风险因素,ISUP 3级和2级较1级风险更高。

要点

  • 68Ga-PSMA PET/CT阴性后55.3%患者出现临床复发,中位无复发生存期15.4个月。
  • ISUP 3级和2级患者临床复发风险较1级更高(HR分别为2.75和2.08)。
  • PSA<0.5 ng/mL且低级别(ISUP1-2)患者阴性结果或支持临床监测探索。

核心结论

  • 68Ga-PSMA PET/CT阴性在早期生化复发(PSA<0.5 ng/mL)且低级别原发前列腺癌(ISUP1和2)患者中可能支持未来前瞻性研究探索临床监测策略。

研究设计与样本

  • 回顾性识别1003例因生化复发接受68Ga-PSMA PET/CT的连续患者数据库中103例阴性患者,中位年龄70岁,中位PSA 0.47 ng/mL,随访至少1年。
  • 根据临床实践选择随访影像判定或排除临床复发,从阴性PET/CT日期至明确疾病日期计算无临床复发生存期。

主要发现

  • 103例中57例(55.3%)检出临床复发,复发部位为前列腺床45.6%、淋巴结38.6%、骨15.8%。
  • 中位无临床复发生存期15.4个月(范围12.1-20.5),12个月无临床复发生存率61.4%(范围50.9-70.4),24个月无临床复发生存率34.8%(范围24-45.8)。
  • ISUP亚组1中位无临床复发生存期20.5个月,显著长于亚组2的12.6个月和亚组3的12.1个月;亚组3的24个月无临床复发生存率9.3%,显著低于亚组1的47.8%和亚组2的33.5%。
  • 单因素和多因素分析中ISUP亚组是临床复发的唯一显著风险因素;亚组3较亚组1的HR为2.75(1.35-5.57),亚组2较亚组1的HR为2.08(1.11-3.88)。

局限性

  • 原文为回顾性研究。
  • 仅纳入随访至少1年的患者。
  • 结论中提出需未来前瞻性研究探索临床监测策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the clinical value of 68Ga-PSMA PET/CT negativity in patients with biochemical recurrent prostate cancer (BCR). METHODS: One hundred three BCR patients (median age, 70 years; median PSA, 0.47 ng/mL) with negative 68Ga-PSMA PET/CT, followed up for at least 1 year, were retrospectively identified in a database of 1003 consecutive patients undergoing 68Ga-PSMA PET/CT for BCR. Clinical recurrence (CR) was determined or excluded on follow-up imaging selected as per clinical practice. Clinical recurrence-free survival (CRFS) was computed from the date of negative 68Ga-PSMA PET/CT to the date of evident disease; frequencies of CRFS were described as per ISUP patient subset (subset 1: ISUP grades 1 and 2; subset 2: ISUP grade 3; subset 3: ISUP grades 4 and 5) and other conventional variables. RESULTS: In 57 patients out of 103 (55.3%), CR was detected in the prostatic fossa (45.6%), nodes (38.6%), and bone (15.8%). The median CRFS was 15.4 months (range, 12.1-20.5), with a CRFS at 12 months in 61.4% of cases (range, 50.9-70.4) whereas the 24-month CRFS was 34.8% (range, 24-45.8). ISUP subset 1 benefited from significantly longer CRFS compared to subset 2 and subset 3 (median CRFS, 20.5 months, 12.6 months, and 12.1 months, respectively). ISUP subset 3 had significantly poorer 24-month CRFS (9.3%) compared to subset 1 (47.8%) and subset 2 (33.5%). At the univariate and multivariate analyses, the ISUP subset was the only significant risk factor for clinical relapse; ISUP subset 3 and subset 2 patients held a higher risk of CR compared to subset 1 patients (HR of 2.75 [1.35-5.57] for subset 3 versus subset 1; HR of 2.08 [1.11-3.88] for subset 2 versus subset 1). CONCLUSION: 68Ga-PSMA PET/CT negativity in early BCR patients (PSA < 0.5 ng/mL) with low-grade primary prostate cancer (ISUP1 and 2) may support the exploration of a clinical surveillance approach in future prospective studies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Celli M, De Giorgi U, Caroli P, et al. Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020. PMID: 32588090. doi:10.1007/s00259-020-04914-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。